Advertisement

Topics

Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 Pipeline Review, H1 2018 [Repo

09:12 EDT 1 Aug 2018 | BioPortfolio Reports

Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 Pipeline Review, H1 2018


Summary


According to the recently published report 'Free Fatty Acid Receptor 4 Pipeline Review, H1 2018'; Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 pipeline Target constitutes close to 9 molecules.


Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 Free Fatty Acid Receptor 4 is a G proteincoupled receptor GPR encoded by FFAR4 gene. It acts as receptor for medium and longchain free fatty acids FFAs. It acts as a receptor for omega3 fatty acids and mediates robust antiinflammatory effects, particularly in macrophages and fat cells. The antiinflammatory effects involve inhibition of TAK1 through a betaarrestin 2 ARRB2/TAB1dependent effect, but independent of the G q/G 11coupled pathway. It mediates potent insulin sensitizing and antidiabetic effects by repressing macrophageinduced tissue inflammation. It mediates the taste of fatty acids.


The report 'Free Fatty Acid Receptor 4 Pipeline Review, H1 2018' outlays comprehensive information on the Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 6 and 3 respectively. Report covers products from therapy areas Metabolic Disorders, Undisclosed and Gastrointestinal which include indications Type 2 Diabetes, Unspecified, Diabetes, Non Alcoholic Fatty Liver Disease NAFLD and NonAlcoholic Steatohepatitis NASH.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4

The report reviews Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 targeted therapeutics and enlists all their major and minor projects

The report assesses Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 Pipeline Review, H1 2018 [Repo

NEXT ARTICLE

More From BioPortfolio on "Free Fatty Acid Receptor 4 G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4 Pipeline Review, H1 2018 [Repo"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...